Industry Standard Research
(ISR) today announced the release of a new market research report titled “
EDC and ePRO Market Trends and Service Provider Performance
.” This report provides the pharmaceutical industry and its service providers with novel insights into the current and future use of these technologies and enables better technology provider selection.
“From a classical market development point of view, EDC technology has finally ‘crossed the chasm’ and has become the de facto data collection mechanism for clinical trials,” Andrew Schafer, President of ISR explained. “While ePRO does not start from the same vantage point – not all studies need a patient-reported outcome component – we do see the ePRO market maturing and several products beginning to emerge as market leaders.”
ISR’s study surveyed 101 site-coordinators and principal investigators with responsibility for data collection at their sites. The data ISR captured represent 710 on-the-ground service experiences across 20 EDC and 14 ePRO products.
“With this data, sponsors can make more informed outsourcing decisions, improve relationships with sites by utilizing technology platforms they prefer, and build efficiencies into study designs,” Schafer explained. “For service providers, this ‘Voice-of-the-Customer’ research offers unique product satisfaction data from end-users on their product and their competitors.”
In addition to end-user satisfaction data, ISR’s report also provides service providers with important insights into current and future EDC and ePRO market trends, including: adoption, usage, preference, study penetration by Phase, and the new ‘eClinical’ service many large CROs are beginning to offer that is sure to impact the competitive landscape.
For more information about ISR’s report, please visit its website
here
.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.